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ApoptosisWe have characterized the transcription proﬁles of parvovirus B19 (B19V) genotype-2 A6 and genotype-3 V9
variants. The A6 RNA proﬁle differs from that of the prototype B19V in both B19V non-permissive and
permissive cells, whereas the overall proﬁle of the V9 RNA in these cells is similar to that of the prototype. A
unique feature we have identiﬁed is that the genotype-2 A6 variant used only one splice acceptor to remove
the ﬁrst intron. We also demonstrated that the inverted terminal repeats (ITRs) of the prototype B19V
support replication of the V9 genome, which produces infectious virus, but not that of the A6 genome, in
B19V-permissive cells. Similar to the proapoptotic nature of the prototype B19V large non-structural protein
(NS1), the A6 and V9 NS1 proteins also are potent inducers of apoptosis in B19V-permissive cells.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human parvovirus B19 (B19V) is the only parvovirus that has been
conﬁrmed to be pathogenic in humans until the discovery of human
bocavirus (Allander et al., 2005). B19V causes a variety of diseases,
including erythema infectiosum (ﬁfth disease) in children, acute or
chronic arthropathy in adults, aplastic crisis in patients with chronic
hemolytic anemia, persistent anemia in immunodeﬁcient and
immunocompromised patients, and fetal hydrops in pregnant
women (Young and Brown, 2004). Recently a number of B19V
variants were reported to vary extensively from the prototype B19V
with respect to genomic sequence, exhibiting greater than 12%
divergence versus the less than 2% divergence characteristic of
previously characterized prototype B19V isolates (Servant et al.,
2002; Hokynar et al., 2002; Nguyen et al., 1999). Of these, the V9
variant, which was isolated from a patient with aplastic crisis,
diverged by about 12% sequence from prototype B19V isolates
(Nguyen et al., 1999). The A6 variant, which was isolated from an
anemic HIV-positive patient, exhibited 12% divergence from the
prototype B19V, and 8% divergence from the V9 variant (Nguyen et al.,
2002). The sequences of other reported A6-related isolates, including
the LaLi isolate, were 98% identical to that of the A6 variant (Hokynar
et al., 2002). Therefore, the human erythrovirus is now classiﬁed into
three distinct genotypes (Servant et al., 2002). Genotype-1 is
composed of all the prototype B19V isolates, genotype-2 includes
the A6, LaLi and their related isolates (Blumel et al., 2005; Norja et al.,ll rights reserved.2006; Sanabani et al., 2006), and genotype-3 comprises the V9 and
V9-related isolates (Sanabani et al., 2006; Candotti et al., 2004).
The B19V genome contains two identical terminal repeats (ITRs) of
approximately 380 nucleotides; these are imperfect palindromes and
form hairpin loops. However, the terminal repeats of genotype-2 and
genotype-3 have not been cloned and sequenced. The genotype-1
replicates restrictively in the erythroid progenitors of human bone
marrow, often producing exceptionally high numbers of progeny
virus in the blood (Ozawa et al., 1986; Srivastava and Lu, 1988). In
contrast, high virus-load viremias of genotype-2 and genotype-3 have
been identiﬁed only occasionally (Blumel et al., 2005; Nguyen et al.,
1999, 2002; Servant et al., 2002; Liefeldt et al., 2005). However, both
of these genotypes have been associated with anemia or aplastic
crisis, indicating their tropism for erythroid cells (Blumel et al., 2005;
Nguyen et al., 1999; Sanabani et al., 2006; Candotti et al., 2004). Cross-
reactivity of 100% in antibody activities among these three genotypes
supports the notion that they comprise only a single serotype (Ekman
et al., 2007). It is not yet known whether the variations among the
genomes of human erythrovirus variants are responsible for their
distinct biological and pathological properties. The P6 promoter
activities of the three genotypes have been shown to be identical, to
be most pronounced in B19V-permissive cells (Ekman et al., 2007).
However, the overall transcriptional proﬁles of the B19V genotype-2
and genotype-3 and their replication competence with the genotype-
1 ITRs have not been explored.
The disease outcome of B19V infection as seen in transient aplastic
crisis, pure red cell aplasia and hydrops fetalis is due to the direct
cytotoxicity of the virus to the erythroid progenitors that are native
host of B19V replication (Brown and Young, 1997). It has been shown
that during B19V infection of primary erythroid progenitor cells and
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S1, progressive apoptosis is induced. In UT7/Epo-S1 cells, this B19V-
induced apoptosis has been shown to be associatedwith expression of
the large non-structural protein (NS1) (Sol et al., 1999; Moffatt et al.,
1998). The amino acid sequence of the A6 and V9 NS1 proteins
diverge from that of the prototype-encoded counterpart by 6.2% and
6.1%, respectively. The potency of both NS1 proteins of the B19V
genotypes 2 and 3 in inducing apoptosis has not yet been examined.
In the current study, we have used a replication competence
system in COS-7 cells to systematically characterize the transcription
proﬁles of the two B19V genotypeswith the cloned nearly-fully length
genome of the A6 (genotype-2) and V9 (genotype-3) variants. We
also investigated the replication competence of the ITRs from the
prototype B19V in the context of the V9 and A6 genomes. Finally, we
evaluated the potency of the two novel NS1 proteins encoded by B19V
genotypes 2 and 3 in inducing apoptosis in B19V-permissive cells.
Results
Transcriptional proﬁles of human erythroviruses V9 and A6
We and others previously showed that the B19V transcription
proﬁle in COS-7 cells transfected with an SV40 replication origin
(SV40-ori)-containing B19V plasmid closely resembles to that from
B19V-infected human bone marrow or erythroid progenitor cells (St
et al., 1991; Guan et al., 2008). Therefore, in this study, we used SV40-
ori-containing A6 and V9 plasmids (pC1V9 and pC1A6) to transfect
COS-7 cells. Replications of these two plasmids in COS-7 cells were
conﬁrmed by Southern blot (data not shown). Transcription proﬁles
were generated from total RNAs isolated from these cells, using RNase
protection and Northern blot analysis.
RNase protection analysis of V9 (A6) RNA
Total RNA isolated from pC1V9- or pC1A6-transfected COS-7 cells
was subjected to RNase protection using probes targeted to the
promoters, intron donor and acceptor sites, and polyadenylation sites.
The B19V genetic map was used as a guide.
V9 (A6) P1 probe
Protection with the V9 (A6) P1 probe, which spans the putative P6
promoter, yielded bands of approximately 192 (193) nts and 58 nts,
respectively. The 192(193)-nt and 58-nt bands represent RNAs that
were transcribed from the P6 promoter and were unspliced and
spliced, respectively, at the ﬁrst donor site (D1). Thus, the P6 RNA
initiation site of V6 (A6) was located at approximately nt 242 (148),
and the D1 donor site was conﬁrmed to be at nt 298 (205). RNA
spliced from the D1 donor site accumulated to levels approximately
10 times greater than that of RNA unspliced at the D1 site, in the cases
of both the V9 and A6 RNAs (Fig. 1B and C, lane 1).
V9 (A6) P2 probe
Protection with the P2 probe, which covers the putative A1-1 and
A1-2 acceptors and D2 donor sites, was predicted to yield ﬁve bands of
563 (561), 471 (472), 351 (352), 274 and 154 nts. The bands at 563
(561) nts, 471 (472) nts and 351 (352) nts, which protected both the
V9 and A6 RNAs from transfected COS-7 cells (Figs. 1B and C, lane 2),
represent RNAs that were unspliced and spliced at A1-1 and A1-2,
respectively; these RNAs were all unspliced at the D2 donor site. The
band at 274 nts represents RNA spliced from the A1-1 acceptor to the
D2 donor, and was protected in both V9 and A6 RNA. These results
conﬁrmed the A1-1 acceptor and the D2 donor at nt 1802 (1709) and
nt 2075 (1982), respectively.
Surprisingly, the 154-nt band that represents RNA spliced at A1-2
acceptor and at the D2 donor was protected in the V9 RNA, but not the
A6 RNA (Figs. 1B and C, lane 2), indicating that the A1-2 acceptor may
not be utilized signiﬁcantly during the processing of A6 RNA isolatedfrom transfected COS-7 cells. This result thus conformed the A1-2
acceptor of the V9 at nt 1922. To examine further the use of the A1-2
acceptor in processing of the A6 RNA in a B19V-permissive cell
system, we transfected pC1A6 into UT7/Epo-S1 cells. Total RNA was
protected with the A6 probe P2; however, a band at 154 nts, which
represents RNA spliced at the A1-2 acceptor and D2 donor, and a band
at 352 nts that represents RNA that is spliced at the A1-2 acceptor but
not at the D2 donor were not protected (Fig. 1D, lane 2). In contrast,
the corresponding bands were both protected in V9 RNA isolated from
pC1V9-transfected UT7/Epo-S1 cells (Fig. 1D, lane 1). The 352-nt
band protected in A6 RNA from COS-7 cells is likely non-speciﬁc
degraded RNA (Fig. 1C, lane 2), as was conﬁrmed repeatedly by RNase
protection assays (data not shown). These results conﬁrmed that the
A1-2 acceptor was not signiﬁcantly utilized in processing A6 RNAs
produced in pC1A6-transfected COS-7 and UT7/Epo-S1 cells.
In cells transfectedwith pC1V9, the levels of RNA spliced at the A1-
1 acceptor were approximately two-fold greater than those of the
RNA spliced at the A1-2 acceptor, which is consistent with the
ﬁndings for infection of erythroid progenitors with genotype-1 B19V
(Guan et al., 2008).
V9 (A6) P3 probe
The P3 probe, which spans the two putative internal polyadenyla-
tion sites and the A2-1 acceptor, was protected to yield bands at
approximately 665 (668) nts, 424 (423) nts, 159 (162) and 133
(124) nts (Figs. 1B and C, lane 3). The 665(668)-nt and 159(162)-nt
bands represent RNAs unspliced and spliced at the A2-1 acceptor,
respectively, which conﬁrmed the A2-1 acceptor at nt 2937 (2844).
The ratio of RNA that was spliced vs. unspliced at the A2-1 site was
approximately 1:6. The 133(124)-nt and 424(423)-nt bands repre-
sent RNAs that were polyadenylated at the internal polyadenylation
sites (pA)p1 and (pA)p2 sites, respectively, which identiﬁed the (pA)
p1 and (pA)2 sites at nt 2562 (2461) and nt 2853 (2760), respectively.
Apparently, about three times more RNA was polyadenylated at the
(pA)p1 site.
V9 (A6) P4 and P5 probes
The P4 probe, which spans the A2-2 acceptor of the second intron,
was protected to yield bands of approximately 243 (244) nts and
80 nts (Figs. 1B and C, lane 4), and these represent RNAs that were
unspliced and spliced RNAs at the A2-2 acceptor site, respectively.
This result conﬁrmed the A2-2 acceptor site at nt 4596 (4503). The
ratio of RNA that was spliced vs unspliced at the A2-2 was
approximately 1:4. The P5 probe, which spans the distal polyadenyla-
tion site, was protected to yield mainly a single band of approximately
190 nts (Figs. 1B and C, lane 5). This indicates that the (pA)d cleavage
site is at nt 4901 and nt 4808 for the V9 and A6, respectively.
Northern blot analysis of V9 and A6 RNA
Northern blot analysis of V9 RNA from COS-7 cells exhibited a
pattern similar to that of the genotype-1 B19V (Beard et al., 1989; Liu
et al., 2004). Hybridization of V9 RNA with the whole NSCap probe
revealed four abundant RNA species that accumulated as bands of
approximately 4.7 kb, 3.0/3.1 kb, 2.2/2.3 kb and 0.5-0.9 kb (Fig. 2, lane
2). These four bands were also detected following hybridization with
the Cap probe (Fig. 2, lane 6), as well as with the NS probe (Fig. 2, lane
4), suggesting that all these RNA species were generated from a single
promoter located upstream of the V9 genome. An RNA band of
approximately 1.8 kb (indicatedwith an asterisk in Fig. 2, lanes 2, 4 and
6) was always hybridizedwith the three probes, and the nature of this
band is unknown. Taken together, ourﬁndings indicate that the overall
proﬁle of V9 transcription is the same as that of genotype-1 B19V.
Hybridization of A6 RNA with the whole NSCap probe revealed
four abundant RNA species similar to those from V9 RNA, i.e. 4.7 kb,
3.1 kb, 2.3 kb and 0.5–0.9 kb bands (Fig. 2, lane 3). These four bands
were also detected following hybridization with the Cap probe (Fig. 2,
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Fig. 2. Northern blot analysis of V9 and A6 RNA. Total RNA isolated from pC1V9- and
pC1A6- transfected COS-7 cells 2 days post-transfection was used for Northern blot
analysis. The blot was hybridized to three V9 DNA probes (NSCap, NS and Cap), which
span various regions of the V9 genome, as indicated. The probes used are diagramed at
the bottom of Fig. 3A. RNA bands detected by each probe are indicated by their
respective sizes in kb to the right side of each blot. Asterisks indicate bands of unknown
identity. RNA maker ladder (Ambion) is shown in lane 1.
279Z. Chen et al. / Virology 394 (2009) 276–285lane 7). However, when it came to hybridization with the NS probe,
unlike the V9 RNA, the A6 RNA did not produce small RNA bands at
0.5–0.9 kb. It is likely that the V9 NS probe hybridized poorly with
these small RNAs, which were spliced at the D1 donor and thus
contained a small exon (∼57 nts), due to sequence variation between
V9 and A6.
Combining the results obtained from RNase protection assay and
Northern blot analysis enabled us to establish the transcription maps
for V9 and A6, respectively, as shown in Fig. 3. In general, alternative
processing of the V9 and A6 RNAs from transfected COS-7 cells
generated different RNA species that are required to produce the non-
structural proteins, i.e. NS1, 8 kDa and 10 kDa, and the structural
proteins, VP1 and VP2. In the case of A6 RNA processing, the failure of
splicing at the A1-2 acceptor does not prevent generation of sufﬁcient
mRNA species encoding for these viral proteins. The R1′, R2′ and R3′
mRNAs of the V9 RNA and the R1′ and R2′mRNAs of the A6 RNAwere
polyadenylated at the (pA)p2 site and did not appear clearly on
Northern blots, indicating that they are likely minor transcripts. In
genotype-1 B19V, RNA polyadenylated at the (pA)p2 accounts for
only 10% of the RNA that is internally polyadenylated (Yoto et al.,
2006). The 4.7 kb R0 mRNA present on maps of V9 and A6 is the full-
length transcript that reads through the (pA)p sites. It was detected in
genotype-1 RNA from transfected cells (Liu et al., 2004), but not in
genotype-1 RNA from virus-infected cells (Ozawa et al., 1987). Since
the genotype-1 RNA proﬁle generated in COS-7 cells following
transfection with a replication-competent construct is similar to
that following infection with genotype-1 virus (St et al., 1991; Yoto et
al., 2006; Guan et al., 2008), we believe that the transcription proﬁles
of A6 and V9 during virus infection are similar to those observed in
transfected cells.
In B19V-permissive UT7/Epo-S1 cells, B19V genotype-1 ITRs support
replication of the incomplete V9 genome, which produces infectious
progeny virus, but not of the A6 genome
The terminal repeats of both genotype-2 and genotype-3 have not
been characterized; therefore, we next examined whether theprototype-1 terminal repeats can support replication of the A6 or
the V9 incomplete genome in UT7/Epo-S1 cells. To this end, we
constructed chimeric genomes of B19VITR-V9 and B19VITR-A6, as
diagramed in Fig. 4A, by inserting the P6-driven NS1- and Cap-
encoding region (NSCap) of the two variants into vectors bearing the
B19V ITRs derived from an infectious clone of genotype-1, pB19-M20
(Zhi et al., 2004). Excised B19V DNAs were transfected into UT7/Epo-
S1 cells and low molecular-weight DNA was extracted for Southern
blot analysis. B19V DNA replication can be identiﬁed by the presence
of a DpnI-digestion-resistant DNA band. As shown in Fig. 4B, the
prototypic ITRs supported replication of the V9 NSCap, but not the A6
NSCap (Fig. 4B, lanes 8 and 10, respectively), suggesting that the A6
NS1 protein may contain mutations that prevent replication of the
genotype-1 ITRs-containing A6 genome. The positive control (the
infectious genotype-1 DNA, M20) generated signiﬁcant quantities of
DpnI-resistant DNA (Fig. 4B, lane 4). In contrast, the negative control
[the NS1-knock-out mutant, M20NS1(−)], did not produce a DpnI-
resistant band (Fig. 4B, lane 6). NS1 expression was conﬁrmed in cells
transfected with the M20, B19VITR-V9 and B19VITR-A6 DNAs, but not
in M20NS1(−)-transfected cells (data not shown). Based on these
ﬁndings, we predict that the ITR structure of the A6 variantmust differ
from that of the prototypic ITR.
We next set out to determine whether transfecting UT7/Epo-S1
cells with B19VITR-V9 or B19VITR-A6 leads the production of
infectious progeny virus. To this end, we transfected UT7/Epo-S1
with B19VITR-V9 or B19VITR-A6 and used lysates of these cells to
infect B19V-permissive ex vivo-expanded CD36+ erythroid progenitor
cells (CD36+ EPCs) (Wong et al., 2008; Guan et al., 2008). Lysates
generated from UT7/Epo-S1 cells transfected with M20 DNA and
M20NS(−) served as a positive and a negative control, respectively.
The production of progeny virus was assayed by the infectivity of
CD36+ EPCs, and quantiﬁed by reverse-transcription (RT)-real time
PCR analysis of spliced VP2 and 11-/10-kDa viral mRNAs produced in
infected CD36+ EPCs. The infectivity of the progeny virus obtained
from lysates of B19VITR-V9-transfected UT7/Epo-S1 cells was nearly
equivalent to that of virus in lysates of M20-transfected (positive
control) cells. In contrast, infectivity of the progeny virus from lysates
from B19VITR-A6-transfected UT7/Epo-S1 cells and M20NS(−)
(negative control) -transfected cells, could not be detected (Fig. 4C).
These results further conﬁrmed that, in UT7/Epo-S1 cells, replication
competence and progeny virus production of the V9 genome is
supported by the genotype-1 B19V ITRs, but that is not the case for the
A6 genome.
The V9 and A6 NS1 proteins are potent inducers of apoptosis in
UT7/Epo-S1 cells
B19V infection induces cell death through an apoptotic pathway,
in both primary erythroid cells and B19V-permissive cell lines (Sol et
al., 1999; Moffatt et al., 1998). This cell death has been attributed to
the NS1 protein. Apoptosis has been reported to be induced in the
NS1-expressing UT7/Epo-S1 as well as in NS1-transfected cells (Sol et
al., 1999; Moffatt et al., 1998; Poole et al., 2004). Given that the A6 and
V9 NS1 proteins diverge approximately 6.0 from that of the genotype-
1, we decided to examine the pro-apoptotic nature of these two novel
NS1 proteins. After initiating apoptosis, cells translocate the mem-
brane phosphatidylserine from the inner face of the plasma
membrane to the cell surface, and this event can be easily detected
by staining with a FITC-conjugated AnnexinV protein. AnnexinV
staining requires the use of living cells. To sort NS1-expressing cells,
we transfected GFP-fused V9 and A6 NS1constructs into UT7/Epo-S1
cells. Two days after transfection, cells then were stained alive with
AnnexinV and PI and were analyzed by ﬂow cytometry. GFP-fused
genotype-1 NS1 and GFP alone were used as positive and negative
controls, respectively. Our results showed that both NS1 proteins of
the A6 and V9 variants behaved much like the genotype-1 B19V NS1,
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Fig. 4. Replication of the V9 and A6 NSCap genomes in the presence of genotype-1 ITRs. (A) Schematic diagrams of B19V DNAs. B19V DNA M20 is the duplex replicative form (RF)
of the genotype-1 genome, which is able to replicate and produce progeny virus in B19V-permissive cells (Zhi et al., 2004). The bubbles within each ITR reﬂect potential inter-
strand folding. The position of the P6 promoter, as well as those of the ORFs for the ﬁve B19V proteins, is also indicated. The prototype B19V ITRs were fused to both ends of the V9
and A6 genomes, at nucleotide numbers shown as ITR nucleotide number/(V9 or A6 nucleotide number), under the diagram of each chimeric construct (B19VITR-V9 or B19VITR-
A6). BssHII sites were used to clone the V9 or A6 genome into the prototype B19V ITRs, as described in the Materials and methods section. (B) Southern blot analysis. Hirt DNA
isolated from excised B19VITR-V9- or B19VITR-A6-transfected UT7/Epo-S1 cells two days post-transfection was digested with EcoRI and DpnI which are indicated as DpnI (−)
and DpnI+ samples, respectively, and these samples were used in Southern blot analysis. Hirt DNA samples isolated from B19V M20- and M20NS1(−)-transfected UT7/Epo-
S1cells were used as positive and negative controls, respectively, of B19V DNA replication. The blot was hybridized to the B19V NSCap DNA probe (Guan et al., 2008). EcoRI-
digested and DpnI-digested M20 DNA (6 ng) were run in lane 1 and lane 2, respectively, and were used as a control of DpnI digestion and a DNA size maker. (C) Quantiﬁcation of
progeny virus production. UT7/Epo-S1 cells were transfected with four B19V DNAs, as shown in panel A. Cell lysates prepared at three days post-transfection were used to infect
CD36+ EPCs, and the infectivity of these cell lysates was quantiﬁed by a RT-real-time-PCR strategy that detected speciﬁcally the VP2 and 11-/10-kDa mRNAs in the CD36+ EPCs
lysates. In each sample, the absolute number of mRNA copies was normalized to the level of β-actin mRNA (104 copies per μl). Results shown represent the average and standard
deviation for data from at least three independent experiments. “UD” denotes undetectable.
281Z. Chen et al. / Virology 394 (2009) 276–285
Fig. 5. Transfection of V9 and A6 NS1 induces apoptosis in B19V-permissive cells. UT7/Epo-S1 cells were transfected with pGFP (as negative control), pGFP-B19VNS1 (positive
control), pGFP-V9NS1 and pGFP-A6NS1. Cells were double-stained with AnnexinV and propidium iodide (PI) at two days post-transfection, and were then subjected to ﬂow
cytometry. Both GFP-negative [GFP(−)] and GFP-positive (GFP+) cell populations were gated to plot cells by PI staining vs. AnnexinV staining. A representative experiment of three
is shown. The average percentages with standard deviation of the AnnexinV+/PI+ and AnnexinV+/PI− populations are shown in the upper right and lower right quadrants,
respectively.
282 Z. Chen et al. / Virology 394 (2009) 276–285inducing a signiﬁcant percentage of the GFP-positive (GFP+) cells in
the population of transfected cells to also become AnnexinV-positive
compared with the GFP control (Fig. 5). However, in GFP negative
[GFP(−)] cells, the population of AnnexinV+ among those trans-
fected with the genotype-1, A6, and V9 GFP-NS1 constructs did not
differ signiﬁcantly from that of the GFP transfection control. More
speciﬁcally, in the GFP+ cell population, transfection of the genotype-
1, V9 and A6 GFP-NS1 constructs induced AnnexinV+/PI- populations
of 21.1%, 22.6% and 22.9%, respectively (cells at early stages of
apoptosis) (Fig. 5). In the same population, genotype-1, V9 and A6
GFP-NS1 induced an AnnexinV+/PI+ population of 17.2%, 14.3% and
12.9%, respectively (cells at late stages of apoptosis) (Fig. 5). The GFP
control only induced an AnnexinV+/PI− and an AnnexinV+/PI+
populations of 12.8% and 4.6%, respectively (Fig. 5). We thus conclude
that both NS1 proteins of the genotypes 2 and 3 have a potency similar
to that of the prototype NS1 to induce apoptosis in UT7/Epo-S1 cells.
Discussion
Recently, human parvovirus B19V has been described to diverge
genetically (Hokynar et al., 2007). However, serological studies of the
three genotypes of B19V conﬁrmed that they belong to one serotype
(Ekman et al., 2007); and all the three genotypes show a tropism for
erythroid cells (Hokynar et al., 2007). Since the transcription proﬁle of
prototype B19V generated by transfecting COS-7 cells is similar to that
during virus infection of B19V-permissive cells (Ozawa et al., 1987;
Beard et al., 1989; Liu et al., 2004; Yoto et al., 2006), we believe that
the transcriptional proﬁles of V9 and A6 variants presented in this
study resemble those during virus infection. A unique feature we have
identiﬁed is that the genotype-2 A6 variant used only one splice
acceptor to remove the ﬁrst intron. However, the overall RNA proﬁle
of the genotype-3 V9 variant is the similar as that of the prototype
B19V.
Prototype B19V replicates exclusively in erythroid progenitors of
human bone marrow, and produces extraordinarily high virus yields
in blood during the early phase of infection (Anderson et al., 1985;
Enders et al., 2006; Ozawa et al., 1986). In contrast, high-titers ofgenotype-2 and genotype-3 are rarely identiﬁed (Blumel et al., 2005;
Liefeldt et al., 2005; Nguyen et al., 1999, 2002; Servant et al., 2002).
More importantly, the genotype-2 variant often persistently presents
in skin; and genotype-3 has been suggested to have remained absent
from wide circulation in Europe (Norja et al., 2006). In the current
study, we have shown that the genotype-2 A6 variant uses only the
ﬁrst acceptor to remove the ﬁrst intron, and therefore fails to produce
the corresponding R5, R7 and R9mRNAs (Fig. 3B). Although the R4, R6
and R8mRNAs encode VP1, VP2 and 10 kDa, respectively, all three are
di-cistronic and in them, the 8-kDa ORF is located upstream of the
VP1/VP2 ORF and the 10-kDa ORF, respectively. It is thus possible that
these di-cistronicmRNAs reduce the translation efﬁciency of VP1/VP2
and 10 kDa. In addition, the inactive A1-2 acceptor site could decrease
the overall number of RNAs spliced at the D2 donor and, in turn,
reduces the levels of protein expression during active virus replica-
tion. Thus, we hypothesize that the inactive A1-2 acceptor is probably
a disadvantage for the processing of A6 virus mRNAs as well as a
disadvantage for protein translation, which could possibly maintain
virus production at a low level.
Sequence alignments among members of all three genotypes (nt
2139-2241 with respect to the prototype B19V J35 isolate, Genbank
accession no.: AY386330) showed that only four variations present in
the A1-2 acceptor region. Between V9 and A6, these nucleotides have
only one difference, an A versus a G at nt 2179. Interestingly, the
position of this nucleotide suggests that it could be the branch point
for the A1-2 acceptor. However, mutation of the G to A in A6 genome
did not rescue splicing at the A1-2 site (data not shown), suggesting
that efﬁcient splicing at the A1-2 site may require an exon and/or
intron splicing enhancer. In fact, the three genotypes vary by
approximately 12% in the region spanning the D2 donor (nt 2305-
2581), which supports that variations in the potential splicing
enhancers may affect splicing at the A1-2 acceptor site. We realized
that the conclusion that the genotype-2 A6 used only one splice
acceptor to remove the ﬁrst intron was drawn only from results
obtained by transfection of the cloned genome of A6 variant.
However, an A6 mutant that bears an A mutation at nt 2180, which
reverts to an identical sequence from nt 1800 to nt 2500 to that of the
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(data not shown). Further investigation into whether the A1-2
acceptor is used with genomes of other genotype-2 and their viruses,
such as the IM-81 (Blumel et al., 2005), is required to demonstrate the
biological importance of the inactive A1-2 acceptor.
The NS1 proteins of the three genotypes diverge signiﬁcantly. The
genotype-2 LaLi and genotype-3 V9 variants diverge nearly 13% from
in the prototype B19V isolate within the NS1-encoding sequence
(Hokynar et al., 2002). On the protein level, however, the LaLi, A6 and
V9 variants are only 6.0% divergent from the B19V prototype. The
B19V NS1 protein is a multifunctional protein. Parvovirus NS1
contains a DNA binding domain at its N-terminus, the conserved
motifs for single-strand nicking activity and an ATP/helicase domain
at the center, and a transcription activation domain at the C-terminus
(Cotmore and Tattersall, 2006). The genotype-1 NS1 has been found
to enhance equally on promoters of all three genotypes (Ekman et al.,
2007). We have shown in this study that the genotype-2 A6 NS1 does
not support replication of the genotype-1 ITR-based A6-NSCap
genome (Fig. 4), suggesting that the 6% divergence either is sufﬁcient
to alter the speciﬁc binding of the A6 NS1 to the genotype-1 ITR, or to
reduce the nicking activity at the terminal resolution site. Interest-
ingly, in a similar genotype-1 ITR-based V9-NSCap genome, the V9
NS1 supported not only genotype-1 ITR-dependent replication, but
also progeny virus production in UT7/Epo-S1 cells. Thus, the V9 NS1 is
fully functional with respect to enabling replication of the B19VITR-V9
genome, as well as synthesis of the single-stranded DNA genome and
its packaging. Therefore, we have shown, for the ﬁrst time, that the
divergent B19V NS1 proteins have genotype-speciﬁc activity in DNA
replication. We hypothesize that the ITR structure of the A6 variant
must differ from that of the genotype-1. Whether the NS1 of other
genotype-2 variants is similar to the A6 NS1, and whether genotype-2
variants share a common ITR structure, require further investigation.
Our results also have conﬁrmed that both the A6 and V9 NS1
proteins possess a similar potency in inducing apoptosis in B19V-
permissive cells, indicating that the NS1 proteins of B19V genotypes 2
and 3 have the same function in the pathogenesis of virus infection as
the prototype NS1. The prototypic NS1-induced cytotoxicity and
apoptosis of infected erythroid progenitors cause the disease out-
comes characteristic of B19V infection (Brown and Young, 1997;
Moffatt et al., 1998; Sol et al., 1999).
Materials and methods
Cells
COS-7 cells (CRL-1651; ATCC) were maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM) with 10% fetal calf serum (FCS) at
37 °C in 5% CO2. UT7/Epo-S1 cells were cultured in DMEM with 10%
FCS and 2 units/ml of Epo [Procrit (Epoetin Alfa), Centocor Ortho
Biotech Inc., Horsham, PA] at 37 °C in 5% CO2. The process of generating
of primary humanCD36+ erythroid progenitor cells (CD36+ EPCs) has
been described elsewhere (Guan et al., 2008; Wong et al., 2008).
Transfection
Per 60-mmdish, 2 μgofDNAwere transfected intoCOS-7 cells, using
Lipofectamine and Plus reagents (Invitrogen) as previously described
(Qiu and Pintel, 2002). UT7/Epo-S1 cells were transfected with 2 μg of
DNA per 2×106 cells using a universal reagent (DNAproject, WA) and
program X005 using the Nucleofector (Lonza, MD).
Plasmid construction
pC1V9 and pC1A6 plasmids
The original A6 plasmid, a pCR-Blunt II TOPO (Invitrogen) vector
into which the full-length coding sequence of A6 (4844 bp) withoutthe 3′- and 5′-ITRs (Genbank accession no.: AY064475) had been
cloned, was a gift from Dr. Kevin Brown. Plasmid pC1A6 was
constructed by replacing the B19V NSCap gene with the A6 sequence
of nt 1-4844 in pC1NS1(−) (Yoto et al., 2006). The pC1 backbone was
constructed by removing the CMV-GFP expression cassette (nt 8-
1477) from pEGFP-C1 (Clontech). A SV40-ori is included in pC1.
The V9-C22 plasmid, consisting of the entire V9 genome except the
3′- and 5′-ITRs (5028 bp, Genbank accession no.: AJ249437) was
obtained from Collection National deCulture de Microorganisms
(Institute Pasteur, Paris, France: CNCM1-2066) as a transferred
material. pC1V9 was constructed by replacing the B19V NSCap gene
with the V9 sequence encompassing nt 1-5028 in pC1NS1(−).
pB19VITR-V9 and pB19VITR-A6 plasmids
All the nucleotide numbers of the geneotype-1 B19V refer to the
J35 isolate (Genbank accession no.: AY386330). To insert the A6
NSCap gene into the J35-ITRs from pM20 (an infectious clone of B19),
we ﬁrst modiﬁed the pN8 (Zhi et al., 2004) to contain the B19V
sequence of nt 182-5412, including two half-ITRs with a BssHII site,
which was named pBssH-N8. Then, the B19V sequences of nt 383-
5209 and nt 383-5210 on pBssH-N8 were replaced with the
corresponding V9 sequence (nt 105-4919) and A6 sequence (nt 12-
4827), respectively, which resulted in the plasmids pBssH-V9 and
pBssH-A6. The BssHII-digested large fragments of pBssH-V9 and
pBssH-A6 were inserted into BssHII-digested pM20, which resulted in
the ﬁnal plasmids pB19VITR-V9 and pB19VITR-A6, respectively. A
schematic diagram of the excised DNAs of B19VITR-A6 and B19VITR-
V9 is shown in Fig. 4A.
GFP-fused NS1 constructs
The NS1 ORFs of V9 (nt 328-2340), A6 (nt 235-2247) and B19V (nt
616-2628)were inserted into BamHI–XhoI digested pcDNAGFP vector,
respectively, to construct the pGFP-V9NS1, pGFP-A6NS1 and pGFP-
B19VNS1, respectively. The pcDNA-GFP was made by inserting the
GFP-coding sequence into the HindIII/BamHI digested pcDNA3
(Invitrogen).
Clones used to generate probes for RNase protection
To map the transcription units of V9 and A6, we used probes V9
(A6) P1, P2, P3, P4 and P5. These probes were constructed by cloning
the following regions of V9 (A6) into BamHI–HindIII digested pGEM3Z
(Promega): nt 193–432 (100–340) [V9 (A6) P1], nt 1710–2272
(1620–2180) [V9 (A6) P2], nt 2430–3095 (2338–3005) [V9 (A6) P3],
nt 4433–4675 (4339–4582) [V9 (A6) P4] and nt 4712–4941 (4619–
4844) [V9 (A6) P5].
RNA isolation, RNase protection and Northern blot analysis
Total RNA was isolated from transfected cells two days post
transfection using TRIZOL reagent (Invitrogen).
An RNase protection assay was performed essentially as previ-
ously described (Naeger et al., 1992; Schoborg and Pintel, 1991).
Probes were generated from BamHI-digested templates by in vitro
transcription with Sp6 polymerase using the MAXIscript® kit
(Ambion) and following the manufacture's instruction. RNA hybri-
dizations for RNase protection were done in the presence of a
substantial excess of probe, and signals were quantiﬁed with the
Storm 856 phosphor imager and Image Quant TL software v2005 (GE
Healthcare). Relative molar ratios of individual RNA species were
determined after adjusting for the number of 32P-labeled uridines
(U) in each protected fragment as previously described (Schoborg
and Pintel, 1991).
Northern blot analyses were performed as previously described
(Pintel et al., 1983; Qiu et al., 2002), using total RNA samples and
32P-labeled DNA probes as indicated. All Northern probes were
digested from corresponding plasmids and are diagramed in Fig. 3.
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At two days after transfection, cells were collected and washed
twice with phosphate-buffered saline. Isolation of low molecular-
weight DNA (Hirt DNA) and Southern blotting were performed
essentially as described previously (Guan et al., 2008). Blots were
hybridized with the V9 NSCap probe (nt 1-5028) (Fig. 3), and signals
were developed by exposing the blots to X-ray ﬁlm.
Virus generation and infection
Transfected UT7/Epo-S1 cells were harvested three days after
transfection. After the cells were frozen and thawed three times,
supernatant was collected. 200 μl of the supernatant were incubated
with 2×105 of CD36+ EPCs with a slow rotation, at 4 °C for 1.5 h.
Infected cells were pelted by low-speed centrifugation, and were
cultured at a concentration of 2×105 cells/ml at 37 °C with 5% CO2. At
3 days postinfection, mRNA was directly isolated from the cells, using
the TurboCapture 8 mRNA kit (Qiagen) according to the manufac-
turer's instructions.
Reverse transcription (RT) and real time-PCR
Isolated mRNA was reverse-transcribed to cDNA using random
hexamers (Promega) and MMLV-RT (Invitrogen), following the
manufacturer's instructions. cDNA copy number was determined by
real-time PCR as described previously (Guan et al., 2008, 2009), using
the TaqMan universal PCR master mix (Takara).
The forward and reverse primers and probe used in real-time PCR
for cDNAs converted from the respective genotype-1 VP2 and 11 kDa
mRNAswere described previously (Guan et al., 2009). The probes used
for cDNAs converted from A6 VP2 and 10-kDa mRNAs were the same
as those used for prototype B19V, respectively, and the forward and
reverse primers used were as follows: for VP2 mRNA: 5′-GACCAGTT-
CAGGAGAATCAT-3′ (nt 1875–1894), 5′-TTCTGAGGCGTTGTATGC-3′
(nt 2911–2894); for 10-kDamRNA: 5′-GAAGCCTTT TACACTCCACTTG-
3′ (nt 1942–1963), 5′-TGGCAGTCCACAATTCTTCAGG-3′ (nt 4565–
4544). The probe used for cDNAs converted from V9 VP2 mRNA was
the same for prototype VP2 mRNA, and the probe used for cDNA
converted from V9 10-kDa mRNA were as the following: 5′FAM-
CGATCAGTTTCGTGAACT/CTACAGATGGA-3′BHQ (D2/A2-2). The for-
ward and reverse primers used for cDNAs converted from V9 VP2 and
11 kDa mRNAs were as follows: for VP2 mRNA: 5′-5′-GACCAGTTCAG-
GAGAATCAT-3′ (nt 1968–1988)-3′, 5′-TTCTGAGGCGTTGTACGC-3′ (nt
3004–2987); for 10-kDa mRNA: 5′-GAAGCTTTTTACACGCTT G-3′ (nt
2035–2056), 5′-TGGCAGTCCACAATTCTTCAG G-3′ (nt 4568–4637).
All the splice donor (D2) and acceptor (A2-1 and A2-2) sites for
prototype B19V were described as previously (Guan et al., 2008), and
those for A6 and V9 are described in Fig. 3.
cDNA copies of β-actin mRNA were quantiﬁed using the forward
and reverse primers and probe as previously reported using JOE-
labeled TaqMan probe (Kammula et al., 1999). Standard curves for β-
actin, VP2 and 11-/10-kDa cDNAs were generated from serial
dilutions of a β-actin cDNA plasmid (Wong et al., 2008) and the
B19V, V9 and A6 VP2 cDNA and 11-/10-kDa cDNA plasmids. The copy
numbers of all B19VmRNAs are presented as copies per μl of the cDNA
reaction mixture, and were normalized with respect to the copy
number of the β-actin mRNA produced in the same reaction.
Flow cytometry analysis
Cells were double-stained live with Cy5-conjugated AnnexinV (BD
Biosciences) and Propidium Iodide (PI, Sigma) in order to detect
apoptotic cells. Staining was carried out according to the manufac-
turer's instructions (BD Biosciences). All samples were analyzed on
the three-laser ﬂow cytometer (LSR II, BD Biosciences) at the FlowCytometry Core of the University Kansas Medical Center. Flow
cytometry data were analyzed using FACS DIVA software (BD
Biosciences).
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